Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 7:2018:1319628.
doi: 10.1155/2018/1319628. eCollection 2018.

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients

Wissam Georges El Hajj Moussa  1   2 , Rebecca Georges Farhat  1   2 , Joseph Claud Nehme  1   2 , Marwan Antoun Sahyoun  1   2 , Alexandre Raymond Schakal  1   2   3 , Alexandre Edmond Jalkh  1   2   3 , Mariana Pierre Abi Karam  1   2 , Georges Georges Azar  1   2   3
Affiliations

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients

Wissam Georges El Hajj Moussa et al. J Ophthalmol. .

Abstract

Aim: The purpose of this study is to evaluate and compare the efficacy of 4 prostaglandin analogues (PGAs) and to determine the incidence of ocular surface disease in newly diagnosed, primary open-angle glaucoma (POAG) patients started on one of those 4 PGAs: bimatoprost (benzalkonium chloride, BAK, 0.3 mg/mL), latanoprost (BAK 0.2 mg/mL), travoprost (polyquad), and tafluprost (BAK-free).

Patients and methods: In this single-center, open-label trial, 32 patients newly diagnosed with POAG were randomly started on one of the four PGAs. All patients underwent a complete ophthalmological exam at presentation and at 1, 3, and 6 months of follow-up. Dry eye disease (DED) was assessed using the original Ocular Surface Disease Index (OSDI) questionnaire, in order to evaluate the impact of the drops on the quality of life of patients.

Results: The mean age was 60.06 years ± 11.76. All four drugs equally and significantly reduced the intraocular pressure (IOP) with respect to the baseline IOP. There was a trend for a slightly greater reduction of IOP with bimatoprost, but the difference was not found to be statistically significant when compared to other PGAs. OSDI scores were significantly superior for travoprost (10.68 ± 5.73) compared to the other three drugs (p < 0.05). Latanoprost caused the most significant eyelash growth and iris discoloration. Conjunctival hyperemia and superficial keratitis occurrence were similar in the four groups.

Conclusion: All prostaglandin analogues equally and significantly reduce the IOP in patients with POAG. According to the results of the OSDI score, latanoprost seems to be the least tolerated among the four drugs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean IOP in POAG patients treated with different prostaglandins in monotherapy, at inclusion and at 1 month, 3 months, and 6 months of follow-up. The percentage of IOP reduction is written above each column. A p value <0.05 is marked by an asterisk. IOP: intraocular pressure; POAG: primary open-angle glaucoma.
Figure 2
Figure 2
Different OSDI scores of patients treated with different prostaglandins. The three dashed lines represent the three subscales analysed to obtain a final OSDI score: vision-related function, ocular symptoms, and environmental triggers. A p value <0.05 is marked by an asterisk. OSDI indicates ocular surface disease index; N, M, and M0 represent, respectively, normal, mild, and moderate eye disease as defined by both physician's assessment and a composite disease severity score; POAG: primary open-angle glaucoma.
See this image and copyright information in PMC

References

    1. Quigley H. A., Broman A. T. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology. 2006;90(3):262–267. doi: 10.1136/bjo.2005.081224. - DOI - PMC - PubMed
    1. Cristina Leske M., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Treatment Trial. Archives of Ophthalmology. 2003;121(1):48–56. doi: 10.1001/archopht.121.1.48. - DOI - PubMed
    1. Lee A. J., McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clinical Ophthalmology. 2010;4:741–764. doi: 10.2147/OPTH.S10441. - DOI - PMC - PubMed
    1. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Current Opinion in Ophthalmology. 1996;7(2):80–86. doi: 10.1097/00055735-199604000-00014. - DOI - PubMed
    1. Vaede D., Baudouin C., Warnet J.-M., Brignole-Baudouin F. Preservatives in eye drops: toward awareness of their toxicity. Journal Français d'Ophtalmologie. 2010;33(7):505–524. doi: 10.1016/j.jfo.2010.06.018. - DOI - PubMed

LinkOut - more resources